Recursion Pharmaceuticals (RXRX) PT Raised to $5.50 at Morgan Stanley
May 14, 2026 8:53 AM
Morgan Stanley analyst Sean Laaman raised the price target on Recursion Pharmaceuticals (NASDAQ: RXRX) to $5.50 (from $5.00) while maintaining a Equalweight rating.
